FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ole Østergaard Thomsen

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Geographic Areas

Denmark

Living Beings

Young Adult

Procedures

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Casper Steenholdt; Ole Østergaard Thomsen; Magid Al-khalaf; Klaus Bendtzen; Jørn Brynskov; Mark A Ainsworth
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
C Steenholdt; Ole Østergaard Thomsen; M A Ainsworth; Jørn Brynskov; C Enevold; Klaus Bendtzen
Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.
Casper Steenholdt; Ole Østergaard Thomsen; Mark Andrew Ainsworth; Jørn Brynskov; Akbar Molazahi; Jakob B Seidelin
Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ole Østergaard Thomsen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Casper Steenholdt; Ole Østergaard Thomsen; Magid Al-khalaf; Klaus Bendtzen; Jørn Brynskov; Mark A Ainsworth
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease.
Inflammatory bowel diseases 2012;18(12):2209-17.
2012: C Steenholdt; Ole Østergaard Thomsen; M A Ainsworth; Jørn Brynskov; C Enevold; Klaus Bendtzen
Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.
Alimentary pharmacology & therapeutics 2012;36(7):650-9.
2012: Casper Steenholdt; Ole Østergaard Thomsen; Mark Andrew Ainsworth; Jørn Brynskov; Akbar Molazahi; Jakob B Seidelin
Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
Scandinavian journal of gastroenterology 2012;47(5):518-27.
2012: Casper Steenholdt; Morten Svenson; Ole Østergaard Thomsen; Klaus Bendtzen; Jørn Brynskov; Mark Andrew Ainsworth
Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease.
Journal of Crohn's & colitis 2012;6(1):108-11.
2011: C Steenholdt; M Svenson; Klaus Bendtzen; Ole Østergaard Thomsen; Jørn Brynskov; M A Ainsworth
Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.
Alimentary pharmacology & therapeutics 2011;34(1):51-8.
2010: Klaus Bendtzen; C Steenholdt; M Ainsworth; Ole Østergaard Thomsen; Jørn Brynskov
Comment on 'Predicting the response to infliximab from trough serum levels'.
Gut 2010;59(9):1298-9; author reply 1299-300.
2010: Casper Steenholdt; Mark Ainsworth; Ole Østergaard Thomsen; Jørn Brynskov; Klaus Bendtzen
[Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
Ugeskrift for laeger 2010;172(1):44-7.
2010: Sixten Borg; Ulf Persson; Tine Jess; Ole Østergaard Thomsen; Tryggve Ljung; Lene Riis; Pia Munkholm
A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observations.
Medical decision making : an international journal of the Society for Medical Decision Making 2010;30(1):132-42.
2009: Ole Haagen Nielsen; Gerhard Rogler; Dieter Hahnloser; Ole Østergaard Thomsen
Diagnosis and management of fistulizing Crohn's disease.
Nature clinical practice. Gastroenterology & hepatology 2009;6(2):92-106.
2009: Klaus Bendtzen; Mark Ainsworth; Casper Steenholdt; Ole Østergaard Thomsen; Jørn Brynskov
Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
Scandinavian journal of gastroenterology 2009;44(7):774-81.
2007: Stefan Schreiber; Mani Khaliq-Kareemi; Ian Craig Lawrance; Ole Østergaard Thomsen; Stephen B Hanauer; Juliet McColm; Ralph Bloomfield; William J Sandborn
Maintenance therapy with certolizumab pegol for Crohn's disease.
The New England journal of medicine 2007;357(3):239-50.
2007: Tine Jess; Lene Riis; Ida Vind; Karen Vanessa Winther; Sixten Borg; Vibeke Binder; Ebbe Langholz; Ole Østergaard Thomsen; Pia Munkholm
Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark.
Inflammatory bowel diseases 2007;13(4):481-9.
2007: Tryggve Ljung; Ole Østergaard Thomsen; Morten Vatn; Per Karlén; Lars Norman Karlsen; Curt Tysk; Stefan U Nilsson; Anders Kilander; Rolf Gillberg; Olof Grip; Stefan Lindgren; Ragnar Befrits; Robert Löfberg
Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia.
Scandinavian journal of gastroenterology 2007;42(2):221-7.
2005: Stefan Schreiber; Paul Rutgeerts; Richard N Fedorak; Munaa Khaliq-Kareemi; Michael A Kamm; Michel Boivin; Charles N Bernstein; Michael Staun; Ole Østergaard Thomsen; Alison Innes
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
Gastroenterology 2005;129(3):807-18.
2005: Ole Østergaard Thomsen; Ole Haagen Nielsen
[Mesalazine for maintenance of medically-induced remission in Crohn disease: a survey of a Cochrane review].
Ugeskrift for laeger 2005;167(33):3015-7.
1998: Karen Vanessa Winther; P Føgh; Ole Østergaard Thomsen; Jørn Brynskov
Inflammatory bowel disease (ulcerative colitis and Crohn's disease): diagnostic criteria and differential diagnosis.
Drugs of today (Barcelona, Spain : 1998) 1998;34(11):935-42.